KPT-9274 is a dual inhibitor of PAK4 and NAMPT enzymes, primarily investigated for its potential in cancer therapy. It targets specific pathways involved in tumor growth, survival, and cellular processes. Researchers are exploring its efficacy in treating various types of cancers, particularly those resistant to conventional treatments. Its ability to modulate key cellular processes and impact the immune system makes it a promising candidate for combination therapies, such as with chemotherapy or immunotherapy, enhancing the effectiveness of existing drugs while potentially reducing side effects. Additionally, preclinical studies suggest applications in reducing tumor metastasis and improving patient outcomes. Ongoing clinical trials aim to further validate its safety and therapeutic benefits in human patients.